<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128293</url>
  </required_header>
  <id_info>
    <org_study_id>209713</org_study_id>
    <nct_id>NCT04128293</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants</brief_title>
  <official_title>A Randomized, Open-Label, Single Dose, Four-Period Crossover Clinical Trial to Assess the Relative Bioavailability of a Tablet Compared to a Capsule of GSK3640254 and to Assess the Effect of Food on the GSK3640254 Tablet in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose, four-period, four sequential, and crossover study&#xD;
      conducted to assess the relative bioavailability of GSK3640254 mesylate tablets and&#xD;
      GSK3640254 mesylate capsules (in the presence of a moderate fat meal). This study will also&#xD;
      evaluate the effect of food (fasted, moderate fat meal, and high fat meal) on the&#xD;
      pharmacokinetics of GSK3640254 mesylate tablet formulation. Participants will be randomized&#xD;
      to receive a single dose of GSK3640254 200 milligram (mg) capsules under moderate fat&#xD;
      conditions and GSK3640254 200 mg tablets under moderate fat, fasted and high fat conditions&#xD;
      in each treatment period. Approximately 16 participants will be enrolled and the duration of&#xD;
      the study will be approximately 54 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    GSK investigating manufacturing site malfunction and assessing impact; Study 209713 Early&#xD;
    Terminated due to risk of potential contamination of study tablets.&#xD;
  </why_stopped>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Actual">November 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Eligible participants will be randomly assigned to 1 of 4 treatment sequences (ABCD, BADC, CDAB, or DCBA) in each treatment period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-infinity) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Cmax (Tmax) for GSK3640254 200 mg Capsules Under Fed Condition (Treatment A)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Cmax (Tmax) for GSK3640254 200 mg Tablets Under Fed, Fasted and High Fat Condition (Treatment B, C and D)</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameter: Hemoglobin</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameter: Hematocrit</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameter: Erythrocytes</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Amylase, Lipase</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Urine Parameter: Specific Gravity</measure>
    <time_frame>Day 2</time_frame>
    <description>Urine samples were collected to analyze the urine parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Urine Parameter: Urobilinogen</measure>
    <time_frame>Day 2</time_frame>
    <description>Urine samples were collected to analyze the urine parameter: urobilinogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Urine Parameter: Potential of Hydrogen (pH)</measure>
    <time_frame>Day 2</time_frame>
    <description>Urine samples were collected to analyze the urine parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF), Corrected QT Interval Using Bazett's Formula (QTcB)</measure>
    <time_frame>Day 1: 2 hours and 4 hours</time_frame>
    <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Days 2, 3, 4, and 5</time_frame>
    <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Pulse Rate</measure>
    <time_frame>Days 2, 3, 4, and 5</time_frame>
    <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Respiratory Rate</measure>
    <time_frame>Days 2, 3, 4, and 5</time_frame>
    <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Body Temperature</measure>
    <time_frame>Days 2, 3, 4, and 5</time_frame>
    <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hemoglobin</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hematocrit</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Amylase, Lipase</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinalysis Parameter: Specific Gravity</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinalysis Parameter: Urobilinogen</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinalysis Parameter: pH</measure>
    <time_frame>Baseline (Day -1) and at Day 2</time_frame>
    <description>Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 hours and 4 hours</time_frame>
    <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP and DBP</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
    <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
    <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
    <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
    <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag Time for Absorption (Tlag) for GSK3640254</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Phase Half-life (t1/2) for GSK3640254</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) for GSK3640254</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for GSK3640254</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Concentration of GSK3640254</measure>
    <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK Concentration Population included all participants who underwent plasma PK sampling and had evaluable PK assay results.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Sequence 1 - Treatment ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 - Treatment BADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 - Treatment CDAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 - Treatment DCBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254 Tablet</intervention_name>
    <description>GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.</description>
    <arm_group_label>Sequence 1 - Treatment ABCD</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment BADC</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment CDAB</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254 Capsule</intervention_name>
    <description>GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.</description>
    <arm_group_label>Sequence 1 - Treatment ABCD</arm_group_label>
    <arm_group_label>Sequence 2 - Treatment BADC</arm_group_label>
    <arm_group_label>Sequence 3 - Treatment CDAB</arm_group_label>
    <arm_group_label>Sequence 4 - Treatment DCBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are healthy as determined by the investigator or medically qualified&#xD;
             designee based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests, and cardiac monitoring (history and ECG).&#xD;
&#xD;
          -  Body weight &gt;=50.0 kilogram (kg) (110 pounds [lbs]) for men and &gt;=45.0 kg (99 lbs) for&#xD;
             women and body mass index within the range 18.5 to 31.0 kg per square meter (m^2)&#xD;
             (inclusive).&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
             Male or female: Female participants: 1. A female participant is eligible to&#xD;
             participate if she is not pregnant or breastfeeding, and at least 1 of the following&#xD;
             conditions applies: a. not a woman of childbearing potential (WOCBP); or Is a WOCBP&#xD;
             and using a nonhormonal contraceptive method that is highly effective, with a failure&#xD;
             rate of &lt;1 percent (%), for 28 days before intervention, during the intervention&#xD;
             period, and for at least 28 days after the last dose of study intervention. The&#xD;
             investigator should evaluate the effectiveness of the contraceptive method in&#xD;
             relationship to the first dose of study intervention. 2. A WOCBP must have a negative&#xD;
             highly sensitive serum pregnancy test at Screening and Day -1. 3. Additional&#xD;
             requirements for pregnancy testing during and after study intervention.&#xD;
&#xD;
          -  The investigator is responsible for review of medical history, menstrual history, and&#xD;
             recent sexual activity to decrease the risk for inclusion of a woman with an early&#xD;
             undetected pregnancy.&#xD;
&#xD;
          -  Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or&#xD;
             motility (example [e.g.], gastroesophageal reflux disease, gastric ulcers, gastritis),&#xD;
             hepatic and/or renal function, that could interfere with the absorption, metabolism,&#xD;
             and/or excretion of the study intervention or render the participant unable to take&#xD;
             oral study intervention.&#xD;
&#xD;
          -  Any history of significant underlying psychiatric disorder, including, but not limited&#xD;
             to, schizophrenia, bipolar disorder with or without psychotic symptoms, other&#xD;
             psychotic disorders, or schizotypal (personality) disorder.&#xD;
&#xD;
          -  Any history of major depressive disorder with or without suicidal features, or anxiety&#xD;
             disorders that required medical intervention (pharmacologic or not) such as&#xD;
             hospitalization or other inpatient treatment and/or chronic (&gt;6 months) outpatient&#xD;
             treatment. Participants with other conditions such as adjustment disorder or dysthymia&#xD;
             that have required shorter term medical therapy (&lt;6 months) without inpatient&#xD;
             treatment and are currently well-controlled clinically or resolved may be considered&#xD;
             for entry after discussion and agreement with the Medical Monitor.&#xD;
&#xD;
          -  Any pre-existing physical or other psychiatric condition (including alcohol or drug&#xD;
             abuse), which, in the opinion of the investigator (with or without psychiatric&#xD;
             evaluation), could interfere with the participant's ability to comply with the dosing&#xD;
             schedule and protocol evaluations or which might compromise the safety of the&#xD;
             participant.&#xD;
&#xD;
          -  Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3&#xD;
             months, or cardiac disease or a family or personal history of long QT syndrome.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen at Screening or within 3 months prior to&#xD;
             starting study intervention.&#xD;
&#xD;
          -  Positive hepatitis C antibody test result at Screening or within 3 months prior to&#xD;
             starting study intervention and positive on reflex to hepatitis C ribonucleic acid.&#xD;
&#xD;
          -  Positive Human immunodeficiency virus-1 and -2 antigen/antibody immunoassay at&#xD;
             Screening.&#xD;
&#xD;
          -  ALT &gt;1.5 Ã— upper limit of normal (ULN). A single repeat of ALT is allowed within a&#xD;
             single Screening period to determine eligibility.&#xD;
&#xD;
          -  Bilirubin &gt;1.5 x ULN (isolated bilirubin &gt;1.5 x ULN is acceptable if bilirubin is&#xD;
             fractionated and direct bilirubin &lt;35%). A single repeat of any laboratory abnormality&#xD;
             is allowed within a single Screening period to determine eligibility.&#xD;
&#xD;
          -  Any acute laboratory abnormality at Screening which, in the opinion of the&#xD;
             investigator, should preclude participation in the study of an investigational&#xD;
             compound.&#xD;
&#xD;
          -  Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of creatine&#xD;
             phosphokinase and lipid abnormalities (e.g., total cholesterol, triglycerides), and&#xD;
             ALT, will exclude a participant from the study unless the investigator can provide a&#xD;
             compelling explanation for the laboratory result(s) and has the assent of the sponsor.&#xD;
             A single repeat of any laboratory abnormality is allowed within a single Screening&#xD;
             period to determine eligibility.&#xD;
&#xD;
          -  A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine&#xD;
             (indicating active current smoking) at Screening or before the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs including&#xD;
             vitamins, herbal and dietary supplements (including Saint John's wort) within 7 days&#xD;
             (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study intervention and for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Treatment with any vaccine within 30 days prior to receiving study intervention.&#xD;
&#xD;
          -  Unwillingness to abstain from excessive consumption of any food or drink containing&#xD;
             grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their&#xD;
             fruit juices within 7 days prior to the first dose of study intervention(s) until the&#xD;
             end of the study.&#xD;
&#xD;
          -  Participation in another concurrent clinical study or prior clinical study (with the&#xD;
             exception of imaging trials) prior to the first dosing day in the current study: 30&#xD;
             days, 5 half-lives, or twice the duration of the biological effect of the study&#xD;
             intervention (whichever is longer).&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliter (mL) within 56 days.&#xD;
&#xD;
          -  Any positive (abnormal) response confirmed by the investigator on a screening&#xD;
             clinician- or qualified designee-administered Columbia Suicide Severity Rating Scale&#xD;
             (C-SSRS).&#xD;
&#xD;
          -  Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the&#xD;
             past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias,&#xD;
             non sustained or sustained ventricular tachycardia, second degree atrioventricular&#xD;
             block Mobitz Type II, third degree atrioventricular block, complete heart block, or&#xD;
             conduction abnormality) which, in the opinion of the investigator or Medical Monitor,&#xD;
             will interfere with the safety for the individual participant.&#xD;
&#xD;
          -  Exclusion criteria for Screening ECG (a single repeat is allowed for eligibility&#xD;
             determination): Heart rate: male &lt;45 or &gt;100 beats per minute (bpm) and female &lt;50 or&#xD;
             &gt;100 bpm, and QTcF interval: male &gt;450 millisecond (ms), female &gt;450 ms.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of &gt;14 units. One unit is equivalent to 8 grams of alcohol: a&#xD;
             half pint (~240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of&#xD;
             spirits.&#xD;
&#xD;
          -  Unable to refrain from tobacco or nicotine-containing products within 3 months prior&#xD;
             to Screening.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or medical&#xD;
             monitor, contraindicates their participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>GSK3640254</keyword>
  <keyword>Human immunodeficiency virus (HIV)</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04128293/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04128293/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a randomized, open-label, single dose, 4 period crossover study in healthy participants conducted at a single center in the United States.</recruitment_details>
      <pre_assignment_details>A total of 16 participants were enrolled in this study. The study was early terminated by sponsor due to a potential contamination issue in the study drug after completion of treatment Period 2. Hence, treatment Periods 3 and 4 were not conducted.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 - Treatment ABCD</title>
          <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between two treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 4. Treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 - Treatment BADC</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between two treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 - Treatment CDAB</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between 2 treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 - Treatment DCBA</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between 2 treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Closed/Terminated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3 (Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1 - Treatment ABCD</title>
          <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between two treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 4. Treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2 - Treatment BADC</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between two treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3 - Treatment CDAB</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between 2 treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4 - Treatment DCBA</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-Test) on Day 1 in treatment Period 1; followed by a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-Reference) on Day 1 in treatment Period 2. There was a washout period of at least 7 days between 2 treatment periods. Participants were planned to receive a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-Test) on Day 1 in treatment Period 3; and a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-Reference) on Day 1 in treatment Period 4. The treatment Periods 3 and 4 were planned but no participants were enrolled due to early termination of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="8.46"/>
                    <measurement group_id="B2" value="33.8" spread="10.21"/>
                    <measurement group_id="B3" value="31.3" spread="7.68"/>
                    <measurement group_id="B4" value="38.0" spread="11.66"/>
                    <measurement group_id="B5" value="34.2" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian - South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.</description>
          <population>PK Parameter Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.51" spread="16.7"/>
                    <measurement group_id="O2" value="31.16" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>0.877</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7585</ci_lower_limit>
            <ci_upper_limit>1.0152</ci_upper_limit>
            <estimate_desc>Relative bioavailability between treatment A and B assessed using analysis of variance with treatment, period, and sequence as fixed effects, participant as a random effect was performed on the natural log-transformed parameter of AUC(0-infinity).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-infinity) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-infinity) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.54" spread="49.4"/>
                    <measurement group_id="O2" value="37.85" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.05" spread="18.2"/>
                    <measurement group_id="O2" value="29.50" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>0.892</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7778</ci_lower_limit>
            <ci_upper_limit>1.0239</ci_upper_limit>
            <estimate_desc>Relative bioavailability between treatment A and B assessed using analysis of variance with treatment, period, and sequence as fixed effects, participant as a random effect was performed on the natural log-transformed parameter of AUC(0-t).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.43" spread="52.3"/>
                    <measurement group_id="O2" value="34.99" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) for GSK3640254 200 mg Capsules and Tablets Under Fed Condition (Treatment A and B)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.151" spread="16.8"/>
                    <measurement group_id="O2" value="1.088" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>0.946</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8594</ci_lower_limit>
            <ci_upper_limit>1.0404</ci_upper_limit>
            <estimate_desc>Relative bioavailability between treatment A and B assessed using analysis of variance with treatment, period, and sequence as fixed effects, participant as a random effect was performed on the natural log-transformed parameter of Cmax.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for GSK3640254 200 mg Tablets Under Fasted and High Fat Condition (Treatment C and D)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5557" spread="71.3"/>
                    <measurement group_id="O2" value="1.168" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Cmax (Tmax) for GSK3640254 200 mg Capsules Under Fed Condition (Treatment A)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Cmax (Tmax) for GSK3640254 200 mg Capsules Under Fed Condition (Treatment A)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.000" lower_limit="4.50" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Cmax (Tmax) for GSK3640254 200 mg Tablets Under Fed, Fasted and High Fat Condition (Treatment B, C and D)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Cmax (Tmax) for GSK3640254 200 mg Tablets Under Fed, Fasted and High Fat Condition (Treatment B, C and D)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.033" lower_limit="3.00" upper_limit="6.07"/>
                    <measurement group_id="O2" value="4.250" lower_limit="2.50" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.500" lower_limit="2.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4252</p_value>
            <p_value_desc>The p-value was assessed based on the Wilcoxon signed-rank test.</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.533</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0000</ci_lower_limit>
            <ci_upper_limit>2.0000</ci_upper_limit>
            <estimate_desc>The median difference and the 90 percent (%) confidence interval of the median difference was estimated from Hodges-Lehmann estimate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3125</p_value>
            <p_value_desc>The p-value was assessed based on the Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7500</ci_lower_limit>
            <ci_upper_limit>5.2500</ci_upper_limit>
            <estimate_desc>The median difference and the 90% confidence interval of the median difference were estimated from Hodges-Lehmann estimate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</title>
        <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</title>
          <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count.</description>
          <population>Safety Population.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.0092"/>
                    <measurement group_id="O2" value="0.028" spread="0.0175"/>
                    <measurement group_id="O3" value="0.036" spread="0.0119"/>
                    <measurement group_id="O4" value="0.038" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="0.0472"/>
                    <measurement group_id="O2" value="0.096" spread="0.0910"/>
                    <measurement group_id="O3" value="0.126" spread="0.0761"/>
                    <measurement group_id="O4" value="0.128" spread="0.0740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.673" spread="0.3314"/>
                    <measurement group_id="O2" value="1.689" spread="0.2283"/>
                    <measurement group_id="O3" value="1.890" spread="0.4366"/>
                    <measurement group_id="O4" value="1.753" spread="0.4307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.365" spread="0.0849"/>
                    <measurement group_id="O2" value="0.384" spread="0.0968"/>
                    <measurement group_id="O3" value="0.434" spread="0.1492"/>
                    <measurement group_id="O4" value="0.410" spread="0.1610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.324" spread="0.6459"/>
                    <measurement group_id="O2" value="2.403" spread="0.6452"/>
                    <measurement group_id="O3" value="2.470" spread="0.6709"/>
                    <measurement group_id="O4" value="2.403" spread="0.6713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.1" spread="22.64"/>
                    <measurement group_id="O2" value="241.5" spread="28.91"/>
                    <measurement group_id="O3" value="271.8" spread="44.08"/>
                    <measurement group_id="O4" value="270.9" spread="40.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: hemoglobin.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: hemoglobin.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" spread="8.61"/>
                    <measurement group_id="O2" value="143.1" spread="8.63"/>
                    <measurement group_id="O3" value="144.8" spread="14.50"/>
                    <measurement group_id="O4" value="145.5" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameter: Hematocrit</title>
        <description>Blood samples were collected to analyze the hematology parameter: hematocrit.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameter: Hematocrit</title>
          <description>Blood samples were collected to analyze the hematology parameter: hematocrit.</description>
          <population>Safety Population.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4406" spread="0.02272"/>
                    <measurement group_id="O2" value="0.4344" spread="0.02477"/>
                    <measurement group_id="O3" value="0.4294" spread="0.04147"/>
                    <measurement group_id="O4" value="0.4345" spread="0.03691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameter: Erythrocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameter: Erythrocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes.</description>
          <population>Safety Population.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.199" spread="0.3468"/>
                    <measurement group_id="O2" value="5.120" spread="0.3829"/>
                    <measurement group_id="O3" value="5.013" spread="0.5337"/>
                    <measurement group_id="O4" value="5.066" spread="0.4719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.</description>
          <population>Safety Population.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.88" spread="4.055"/>
                    <measurement group_id="O2" value="85.00" spread="4.184"/>
                    <measurement group_id="O3" value="85.84" spread="4.373"/>
                    <measurement group_id="O4" value="85.90" spread="4.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.</description>
          <population>Safety Population.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.01" spread="1.864"/>
                    <measurement group_id="O2" value="28.06" spread="1.905"/>
                    <measurement group_id="O3" value="28.94" spread="1.614"/>
                    <measurement group_id="O4" value="28.73" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</title>
        <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</title>
          <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.</description>
          <population>Safety Population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.774" spread="0.2447"/>
                    <measurement group_id="O2" value="4.780" spread="0.1336"/>
                    <measurement group_id="O3" value="4.843" spread="0.3617"/>
                    <measurement group_id="O4" value="4.838" spread="0.2467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.853" spread="1.0266"/>
                    <measurement group_id="O2" value="4.630" spread="0.8081"/>
                    <measurement group_id="O3" value="5.028" spread="1.5207"/>
                    <measurement group_id="O4" value="4.960" spread="1.3009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.048" spread="0.5887"/>
                    <measurement group_id="O2" value="0.989" spread="0.6469"/>
                    <measurement group_id="O3" value="1.509" spread="1.1537"/>
                    <measurement group_id="O4" value="1.379" spread="0.8660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anion gap</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="1.58"/>
                    <measurement group_id="O2" value="9.9" spread="1.25"/>
                    <measurement group_id="O3" value="11.1" spread="2.03"/>
                    <measurement group_id="O4" value="10.9" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.473" spread="0.0453"/>
                    <measurement group_id="O2" value="2.430" spread="0.0609"/>
                    <measurement group_id="O3" value="2.421" spread="0.1025"/>
                    <measurement group_id="O4" value="2.431" spread="0.1005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="1.16"/>
                    <measurement group_id="O2" value="31.3" spread="1.04"/>
                    <measurement group_id="O3" value="30.1" spread="2.30"/>
                    <measurement group_id="O4" value="30.5" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.1" spread="0.99"/>
                    <measurement group_id="O2" value="101.0" spread="1.60"/>
                    <measurement group_id="O3" value="101.5" spread="2.14"/>
                    <measurement group_id="O4" value="101.6" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.173" spread="0.1278"/>
                    <measurement group_id="O2" value="1.201" spread="0.0606"/>
                    <measurement group_id="O3" value="1.199" spread="0.1929"/>
                    <measurement group_id="O4" value="1.230" spread="0.1292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="0.334"/>
                    <measurement group_id="O2" value="4.50" spread="0.239"/>
                    <measurement group_id="O3" value="4.28" spread="0.282"/>
                    <measurement group_id="O4" value="4.36" spread="0.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.1" spread="0.99"/>
                    <measurement group_id="O2" value="137.5" spread="2.00"/>
                    <measurement group_id="O3" value="138.5" spread="1.31"/>
                    <measurement group_id="O4" value="138.4" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.785" spread="0.9271"/>
                    <measurement group_id="O2" value="4.509" spread="1.1031"/>
                    <measurement group_id="O3" value="4.351" spread="1.0179"/>
                    <measurement group_id="O4" value="4.096" spread="0.8941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase</title>
        <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase</title>
          <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.</description>
          <population>Safety Population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1" spread="36.01"/>
                    <measurement group_id="O2" value="116.8" spread="48.18"/>
                    <measurement group_id="O3" value="94.8" spread="44.83"/>
                    <measurement group_id="O4" value="111.9" spread="55.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.8" spread="9.54"/>
                    <measurement group_id="O2" value="122.1" spread="20.33"/>
                    <measurement group_id="O3" value="120.1" spread="18.18"/>
                    <measurement group_id="O4" value="122.3" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="3.09"/>
                    <measurement group_id="O2" value="15.0" spread="3.46"/>
                    <measurement group_id="O3" value="17.9" spread="14.22"/>
                    <measurement group_id="O4" value="18.5" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" spread="8.89"/>
                    <measurement group_id="O2" value="58.3" spread="8.07"/>
                    <measurement group_id="O3" value="57.5" spread="14.82"/>
                    <measurement group_id="O4" value="60.8" spread="20.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="2.39"/>
                    <measurement group_id="O2" value="14.4" spread="2.56"/>
                    <measurement group_id="O3" value="15.6" spread="3.11"/>
                    <measurement group_id="O4" value="16.1" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyl transferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="7.74"/>
                    <measurement group_id="O2" value="17.5" spread="7.54"/>
                    <measurement group_id="O3" value="28.4" spread="24.07"/>
                    <measurement group_id="O4" value="28.3" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</title>
        <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</title>
          <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.</description>
          <population>Safety Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.9" spread="60.74"/>
                    <measurement group_id="O2" value="282.6" spread="60.69"/>
                    <measurement group_id="O3" value="287.0" spread="72.44"/>
                    <measurement group_id="O4" value="276.6" spread="60.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.84" spread="12.612"/>
                    <measurement group_id="O2" value="92.71" spread="12.136"/>
                    <measurement group_id="O3" value="84.95" spread="13.200"/>
                    <measurement group_id="O4" value="82.78" spread="13.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85" spread="2.838"/>
                    <measurement group_id="O2" value="10.78" spread="3.283"/>
                    <measurement group_id="O3" value="12.24" spread="5.172"/>
                    <measurement group_id="O4" value="11.09" spread="4.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.526"/>
                    <measurement group_id="O2" value="2.13" spread="0.607"/>
                    <measurement group_id="O3" value="2.29" spread="1.241"/>
                    <measurement group_id="O4" value="2.14" spread="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein</title>
        <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein</title>
          <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="1.49"/>
                    <measurement group_id="O2" value="44.0" spread="1.77"/>
                    <measurement group_id="O3" value="45.9" spread="2.85"/>
                    <measurement group_id="O4" value="46.4" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="3.20"/>
                    <measurement group_id="O2" value="27.1" spread="4.02"/>
                    <measurement group_id="O3" value="25.3" spread="3.11"/>
                    <measurement group_id="O4" value="25.8" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="2.56"/>
                    <measurement group_id="O2" value="71.1" spread="3.36"/>
                    <measurement group_id="O3" value="71.1" spread="3.98"/>
                    <measurement group_id="O4" value="72.1" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Chemistry Parameters: Amylase, Lipase</title>
        <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Chemistry Parameters: Amylase, Lipase</title>
          <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase.</description>
          <population>Safety Population.</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="11.51"/>
                    <measurement group_id="O2" value="54.3" spread="14.39"/>
                    <measurement group_id="O3" value="66.3" spread="26.29"/>
                    <measurement group_id="O4" value="68.8" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="10.00"/>
                    <measurement group_id="O2" value="21.6" spread="13.67"/>
                    <measurement group_id="O3" value="21.6" spread="11.69"/>
                    <measurement group_id="O4" value="22.9" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Urine Parameter: Specific Gravity</title>
        <description>Urine samples were collected to analyze the urine parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Urine Parameter: Specific Gravity</title>
          <description>Urine samples were collected to analyze the urine parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.</description>
          <population>Safety Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0169" spread="0.00666"/>
                    <measurement group_id="O2" value="1.0108" spread="0.00774"/>
                    <measurement group_id="O3" value="1.0165" spread="0.00590"/>
                    <measurement group_id="O4" value="1.0150" spread="0.00632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Urine Parameter: Urobilinogen</title>
        <description>Urine samples were collected to analyze the urine parameter: urobilinogen.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Urine Parameter: Urobilinogen</title>
          <description>Urine samples were collected to analyze the urine parameter: urobilinogen.</description>
          <population>Safety Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3860" spread="0.00000"/>
                    <measurement group_id="O2" value="5.0790" spread="4.78853"/>
                    <measurement group_id="O3" value="8.4650" spread="7.00969"/>
                    <measurement group_id="O4" value="5.0790" spread="4.78853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Urine Parameter: Potential of Hydrogen (pH)</title>
        <description>Urine samples were collected to analyze the urine parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Urine Parameter: Potential of Hydrogen (pH)</title>
          <description>Urine samples were collected to analyze the urine parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).</description>
          <population>Safety Population.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="0.518"/>
                    <measurement group_id="O2" value="6.31" spread="0.704"/>
                    <measurement group_id="O3" value="6.31" spread="0.530"/>
                    <measurement group_id="O4" value="6.13" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF), Corrected QT Interval Using Bazett's Formula (QTcB)</title>
        <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.</description>
        <time_frame>Day 1: 2 hours and 4 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF), Corrected QT Interval Using Bazett's Formula (QTcB)</title>
          <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.</description>
          <population>Safety Population.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.3" spread="9.62"/>
                    <measurement group_id="O2" value="173.4" spread="11.07"/>
                    <measurement group_id="O3" value="158.3" spread="17.85"/>
                    <measurement group_id="O4" value="156.9" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.4" spread="11.25"/>
                    <measurement group_id="O2" value="173.0" spread="9.55"/>
                    <measurement group_id="O3" value="157.5" spread="14.29"/>
                    <measurement group_id="O4" value="149.6" spread="17.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="6.60"/>
                    <measurement group_id="O2" value="94.3" spread="6.02"/>
                    <measurement group_id="O3" value="91.5" spread="11.10"/>
                    <measurement group_id="O4" value="92.6" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" spread="5.88"/>
                    <measurement group_id="O2" value="91.4" spread="7.95"/>
                    <measurement group_id="O3" value="91.3" spread="9.13"/>
                    <measurement group_id="O4" value="92.1" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.1" spread="22.03"/>
                    <measurement group_id="O2" value="372.8" spread="21.74"/>
                    <measurement group_id="O3" value="405.8" spread="25.73"/>
                    <measurement group_id="O4" value="387.6" spread="29.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.0" spread="22.55"/>
                    <measurement group_id="O2" value="391.0" spread="25.95"/>
                    <measurement group_id="O3" value="411.5" spread="30.29"/>
                    <measurement group_id="O4" value="398.3" spread="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.8" spread="14.41"/>
                    <measurement group_id="O2" value="376.0" spread="20.09"/>
                    <measurement group_id="O3" value="406.1" spread="23.12"/>
                    <measurement group_id="O4" value="399.9" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.9" spread="18.00"/>
                    <measurement group_id="O2" value="381.1" spread="15.37"/>
                    <measurement group_id="O3" value="406.5" spread="24.60"/>
                    <measurement group_id="O4" value="410.6" spread="20.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.3" spread="13.54"/>
                    <measurement group_id="O2" value="377.9" spread="20.92"/>
                    <measurement group_id="O3" value="406.6" spread="26.45"/>
                    <measurement group_id="O4" value="406.8" spread="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.1" spread="18.55"/>
                    <measurement group_id="O2" value="376.5" spread="12.93"/>
                    <measurement group_id="O3" value="404.5" spread="28.43"/>
                    <measurement group_id="O4" value="417.4" spread="24.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
        <time_frame>Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
          <population>Safety Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.0" spread="8.05"/>
                    <measurement group_id="O2" value="115.1" spread="6.77"/>
                    <measurement group_id="O3" value="116.4" spread="10.25"/>
                    <measurement group_id="O4" value="118.3" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="8.85"/>
                    <measurement group_id="O2" value="115.6" spread="10.34"/>
                    <measurement group_id="O3" value="117.1" spread="7.57"/>
                    <measurement group_id="O4" value="115.6" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="8.45"/>
                    <measurement group_id="O2" value="117.6" spread="13.10"/>
                    <measurement group_id="O3" value="113.6" spread="11.33"/>
                    <measurement group_id="O4" value="116.5" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" spread="8.58"/>
                    <measurement group_id="O2" value="113.9" spread="10.58"/>
                    <measurement group_id="O3" value="113.8" spread="9.29"/>
                    <measurement group_id="O4" value="113.6" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" spread="6.61"/>
                    <measurement group_id="O2" value="69.6" spread="6.61"/>
                    <measurement group_id="O3" value="71.0" spread="8.16"/>
                    <measurement group_id="O4" value="71.0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="7.52"/>
                    <measurement group_id="O2" value="66.3" spread="9.75"/>
                    <measurement group_id="O3" value="68.6" spread="7.13"/>
                    <measurement group_id="O4" value="71.9" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="9.71"/>
                    <measurement group_id="O2" value="68.9" spread="10.76"/>
                    <measurement group_id="O3" value="72.0" spread="9.38"/>
                    <measurement group_id="O4" value="73.4" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="10.09"/>
                    <measurement group_id="O2" value="68.3" spread="11.65"/>
                    <measurement group_id="O3" value="72.4" spread="7.95"/>
                    <measurement group_id="O4" value="70.6" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Pulse Rate</title>
        <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
        <time_frame>Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Pulse Rate</title>
          <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="6.19"/>
                    <measurement group_id="O2" value="61.3" spread="9.79"/>
                    <measurement group_id="O3" value="66.0" spread="11.75"/>
                    <measurement group_id="O4" value="64.5" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="7.54"/>
                    <measurement group_id="O2" value="61.4" spread="9.07"/>
                    <measurement group_id="O3" value="63.4" spread="8.94"/>
                    <measurement group_id="O4" value="67.9" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="9.51"/>
                    <measurement group_id="O2" value="61.9" spread="7.20"/>
                    <measurement group_id="O3" value="67.1" spread="8.39"/>
                    <measurement group_id="O4" value="64.5" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="8.47"/>
                    <measurement group_id="O2" value="62.8" spread="11.21"/>
                    <measurement group_id="O3" value="67.4" spread="5.76"/>
                    <measurement group_id="O4" value="65.8" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Respiratory Rate</title>
        <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
        <time_frame>Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Respiratory Rate</title>
          <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="2.71"/>
                    <measurement group_id="O2" value="13.8" spread="2.25"/>
                    <measurement group_id="O3" value="14.0" spread="2.83"/>
                    <measurement group_id="O4" value="14.0" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="1.98"/>
                    <measurement group_id="O2" value="15.5" spread="2.33"/>
                    <measurement group_id="O3" value="14.3" spread="1.98"/>
                    <measurement group_id="O4" value="14.3" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="0.00"/>
                    <measurement group_id="O2" value="16.0" spread="1.07"/>
                    <measurement group_id="O3" value="14.5" spread="1.41"/>
                    <measurement group_id="O4" value="14.3" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="3.62"/>
                    <measurement group_id="O2" value="15.3" spread="3.01"/>
                    <measurement group_id="O3" value="15.8" spread="2.25"/>
                    <measurement group_id="O4" value="14.5" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values for Body Temperature</title>
        <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
        <time_frame>Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values for Body Temperature</title>
          <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
          <population>Safety Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.15" spread="0.378"/>
                    <measurement group_id="O2" value="36.28" spread="0.292"/>
                    <measurement group_id="O3" value="36.15" spread="0.548"/>
                    <measurement group_id="O4" value="36.16" spread="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.13" spread="0.219"/>
                    <measurement group_id="O2" value="36.34" spread="0.297"/>
                    <measurement group_id="O3" value="36.19" spread="0.230"/>
                    <measurement group_id="O4" value="36.11" spread="0.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.21" spread="0.295"/>
                    <measurement group_id="O2" value="36.09" spread="0.242"/>
                    <measurement group_id="O3" value="36.26" spread="0.407"/>
                    <measurement group_id="O4" value="36.21" spread="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.33" spread="0.238"/>
                    <measurement group_id="O2" value="36.41" spread="0.309"/>
                    <measurement group_id="O3" value="36.24" spread="0.213"/>
                    <measurement group_id="O4" value="36.36" spread="0.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</title>
        <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count</title>
          <description>Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.0099"/>
                    <measurement group_id="O2" value="0.003" spread="0.0149"/>
                    <measurement group_id="O3" value="-0.004" spread="0.0074"/>
                    <measurement group_id="O4" value="-0.003" spread="0.0071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.0338"/>
                    <measurement group_id="O2" value="0.005" spread="0.0278"/>
                    <measurement group_id="O3" value="0.009" spread="0.0259"/>
                    <measurement group_id="O4" value="0.010" spread="0.0169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.170" spread="0.3945"/>
                    <measurement group_id="O2" value="-0.154" spread="0.5025"/>
                    <measurement group_id="O3" value="0.015" spread="0.1927"/>
                    <measurement group_id="O4" value="-0.123" spread="0.1959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.0487"/>
                    <measurement group_id="O2" value="0.004" spread="0.0721"/>
                    <measurement group_id="O3" value="0.019" spread="0.0884"/>
                    <measurement group_id="O4" value="-0.005" spread="0.0767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.214" spread="0.4939"/>
                    <measurement group_id="O2" value="-0.135" spread="0.2945"/>
                    <measurement group_id="O3" value="-0.166" spread="0.7631"/>
                    <measurement group_id="O4" value="-0.234" spread="0.5199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="22.63"/>
                    <measurement group_id="O2" value="7.6" spread="11.84"/>
                    <measurement group_id="O3" value="6.1" spread="18.76"/>
                    <measurement group_id="O4" value="5.3" spread="18.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="4.34"/>
                    <measurement group_id="O2" value="4.0" spread="4.93"/>
                    <measurement group_id="O3" value="3.3" spread="6.50"/>
                    <measurement group_id="O4" value="4.0" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
        <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
          <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0179" spread="0.01374"/>
                    <measurement group_id="O2" value="0.0116" spread="0.01430"/>
                    <measurement group_id="O3" value="0.0063" spread="0.01884"/>
                    <measurement group_id="O4" value="0.0114" spread="0.01963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.241" spread="0.1604"/>
                    <measurement group_id="O2" value="0.163" spread="0.1521"/>
                    <measurement group_id="O3" value="0.100" spread="0.2321"/>
                    <measurement group_id="O4" value="0.154" spread="0.2329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.416"/>
                    <measurement group_id="O2" value="-0.49" spread="0.582"/>
                    <measurement group_id="O3" value="-0.45" spread="0.672"/>
                    <measurement group_id="O4" value="-0.39" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.245"/>
                    <measurement group_id="O2" value="-0.05" spread="0.220"/>
                    <measurement group_id="O3" value="0.09" spread="0.387"/>
                    <measurement group_id="O4" value="-0.13" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</title>
        <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen</title>
          <description>Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.3778"/>
                    <measurement group_id="O2" value="-0.049" spread="0.2568"/>
                    <measurement group_id="O3" value="-0.168" spread="0.2530"/>
                    <measurement group_id="O4" value="-0.173" spread="0.3159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.498" spread="0.7449"/>
                    <measurement group_id="O2" value="0.275" spread="0.4277"/>
                    <measurement group_id="O3" value="0.310" spread="0.4079"/>
                    <measurement group_id="O4" value="0.243" spread="0.3383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.1434"/>
                    <measurement group_id="O2" value="-0.033" spread="0.1849"/>
                    <measurement group_id="O3" value="0.013" spread="0.5576"/>
                    <measurement group_id="O4" value="-0.118" spread="0.4461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anion gap</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.89"/>
                    <measurement group_id="O2" value="-0.8" spread="2.25"/>
                    <measurement group_id="O3" value="-0.6" spread="1.41"/>
                    <measurement group_id="O4" value="-0.9" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.0674"/>
                    <measurement group_id="O2" value="0.053" spread="0.0794"/>
                    <measurement group_id="O3" value="0.026" spread="0.0713"/>
                    <measurement group_id="O4" value="0.036" spread="0.0965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.19"/>
                    <measurement group_id="O2" value="0.9" spread="1.46"/>
                    <measurement group_id="O3" value="1.3" spread="0.89"/>
                    <measurement group_id="O4" value="1.6" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.49"/>
                    <measurement group_id="O2" value="0.1" spread="2.17"/>
                    <measurement group_id="O3" value="-0.1" spread="1.25"/>
                    <measurement group_id="O4" value="0.0" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.1165"/>
                    <measurement group_id="O2" value="0.023" spread="0.1499"/>
                    <measurement group_id="O3" value="0.044" spread="0.1327"/>
                    <measurement group_id="O4" value="0.075" spread="0.1144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.238"/>
                    <measurement group_id="O2" value="0.26" spread="0.226"/>
                    <measurement group_id="O3" value="0.08" spread="0.198"/>
                    <measurement group_id="O4" value="0.16" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.60"/>
                    <measurement group_id="O2" value="-0.3" spread="2.25"/>
                    <measurement group_id="O3" value="0.4" spread="1.30"/>
                    <measurement group_id="O4" value="0.3" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.8640"/>
                    <measurement group_id="O2" value="-0.325" spread="0.7951"/>
                    <measurement group_id="O3" value="0.090" spread="1.7057"/>
                    <measurement group_id="O4" value="-0.165" spread="1.4390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase</title>
        <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase</title>
          <description>Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.3" spread="60.14"/>
                    <measurement group_id="O2" value="-53.6" spread="72.20"/>
                    <measurement group_id="O3" value="-24.5" spread="24.18"/>
                    <measurement group_id="O4" value="-7.4" spread="34.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="16.62"/>
                    <measurement group_id="O2" value="-13.3" spread="19.02"/>
                    <measurement group_id="O3" value="-12.9" spread="8.22"/>
                    <measurement group_id="O4" value="-10.8" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.56"/>
                    <measurement group_id="O2" value="-2.1" spread="3.00"/>
                    <measurement group_id="O3" value="0.4" spread="2.50"/>
                    <measurement group_id="O4" value="1.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="8.11"/>
                    <measurement group_id="O2" value="-3.8" spread="4.77"/>
                    <measurement group_id="O3" value="-3.0" spread="5.58"/>
                    <measurement group_id="O4" value="0.3" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.03"/>
                    <measurement group_id="O2" value="-2.3" spread="2.38"/>
                    <measurement group_id="O3" value="-0.5" spread="1.07"/>
                    <measurement group_id="O4" value="0.0" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyl transferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.13"/>
                    <measurement group_id="O2" value="0.6" spread="1.77"/>
                    <measurement group_id="O3" value="-1.1" spread="1.46"/>
                    <measurement group_id="O4" value="-1.3" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</title>
        <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin</title>
          <description>Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="18.71"/>
                    <measurement group_id="O2" value="-13.5" spread="28.10"/>
                    <measurement group_id="O3" value="-14.1" spread="37.84"/>
                    <measurement group_id="O4" value="-24.5" spread="50.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="6.736"/>
                    <measurement group_id="O2" value="1.54" spread="6.292"/>
                    <measurement group_id="O3" value="1.75" spread="8.188"/>
                    <measurement group_id="O4" value="-0.43" spread="7.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.364"/>
                    <measurement group_id="O2" value="3.05" spread="2.117"/>
                    <measurement group_id="O3" value="1.13" spread="4.318"/>
                    <measurement group_id="O4" value="-0.03" spread="4.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.590"/>
                    <measurement group_id="O2" value="0.51" spread="0.449"/>
                    <measurement group_id="O3" value="0.06" spread="0.609"/>
                    <measurement group_id="O4" value="-0.09" spread="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein</title>
        <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein</title>
          <description>Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.83"/>
                    <measurement group_id="O2" value="-0.3" spread="2.38"/>
                    <measurement group_id="O3" value="0.1" spread="1.55"/>
                    <measurement group_id="O4" value="0.6" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.85"/>
                    <measurement group_id="O2" value="-0.1" spread="2.30"/>
                    <measurement group_id="O3" value="-0.4" spread="2.13"/>
                    <measurement group_id="O4" value="0.1" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.60"/>
                    <measurement group_id="O2" value="-0.4" spread="3.78"/>
                    <measurement group_id="O3" value="-0.3" spread="2.87"/>
                    <measurement group_id="O4" value="0.8" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Amylase, Lipase</title>
        <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Amylase, Lipase</title>
          <description>Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="9.29"/>
                    <measurement group_id="O2" value="1.5" spread="10.21"/>
                    <measurement group_id="O3" value="4.0" spread="5.98"/>
                    <measurement group_id="O4" value="6.5" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="16.34"/>
                    <measurement group_id="O2" value="-7.5" spread="9.93"/>
                    <measurement group_id="O3" value="-3.9" spread="3.87"/>
                    <measurement group_id="O4" value="-2.6" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinalysis Parameter: Specific Gravity</title>
        <description>Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinalysis Parameter: Specific Gravity</title>
          <description>Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0034" spread="0.01006"/>
                    <measurement group_id="O2" value="-0.0028" spread="0.01341"/>
                    <measurement group_id="O3" value="-0.0009" spread="0.01284"/>
                    <measurement group_id="O4" value="-0.0024" spread="0.01097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinalysis Parameter: Urobilinogen</title>
        <description>Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinalysis Parameter: Urobilinogen</title>
          <description>Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6930" spread="4.78853"/>
                    <measurement group_id="O2" value="0.0000" spread="7.23957"/>
                    <measurement group_id="O3" value="1.6930" spread="8.67994"/>
                    <measurement group_id="O4" value="-1.6930" spread="4.78853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinalysis Parameter: pH</title>
        <description>Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day -1) and at Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinalysis Parameter: pH</title>
          <description>Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, prior to the first dose of study drug administration. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.463"/>
                    <measurement group_id="O2" value="0.19" spread="0.651"/>
                    <measurement group_id="O3" value="0.44" spread="0.623"/>
                    <measurement group_id="O4" value="0.25" spread="0.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB</title>
        <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 hours and 4 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB</title>
          <description>Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="3.81"/>
                    <measurement group_id="O2" value="2.3" spread="8.24"/>
                    <measurement group_id="O3" value="-0.3" spread="5.85"/>
                    <measurement group_id="O4" value="5.4" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="4.79"/>
                    <measurement group_id="O2" value="1.9" spread="6.24"/>
                    <measurement group_id="O3" value="-1.0" spread="7.21"/>
                    <measurement group_id="O4" value="-1.9" spread="15.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.81"/>
                    <measurement group_id="O2" value="3.5" spread="6.74"/>
                    <measurement group_id="O3" value="0.3" spread="4.46"/>
                    <measurement group_id="O4" value="1.6" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="5.37"/>
                    <measurement group_id="O2" value="0.6" spread="4.44"/>
                    <measurement group_id="O3" value="0.0" spread="4.44"/>
                    <measurement group_id="O4" value="1.1" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="11.37"/>
                    <measurement group_id="O2" value="-15.6" spread="12.64"/>
                    <measurement group_id="O3" value="5.5" spread="7.96"/>
                    <measurement group_id="O4" value="-12.6" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="16.40"/>
                    <measurement group_id="O2" value="2.6" spread="10.69"/>
                    <measurement group_id="O3" value="11.3" spread="13.72"/>
                    <measurement group_id="O4" value="-2.0" spread="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="8.92"/>
                    <measurement group_id="O2" value="-10.5" spread="6.57"/>
                    <measurement group_id="O3" value="-0.1" spread="6.36"/>
                    <measurement group_id="O4" value="-7.5" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="11.34"/>
                    <measurement group_id="O2" value="-5.4" spread="6.67"/>
                    <measurement group_id="O3" value="0.3" spread="7.74"/>
                    <measurement group_id="O4" value="3.3" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="14.38"/>
                    <measurement group_id="O2" value="-8.1" spread="13.15"/>
                    <measurement group_id="O3" value="-3.1" spread="8.79"/>
                    <measurement group_id="O4" value="-4.6" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="16.44"/>
                    <measurement group_id="O2" value="-9.5" spread="9.81"/>
                    <measurement group_id="O3" value="-5.3" spread="11.66"/>
                    <measurement group_id="O4" value="6.0" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP and DBP</title>
        <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP and DBP</title>
          <description>SBP and DBP were measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.87"/>
                    <measurement group_id="O2" value="-2.0" spread="4.54"/>
                    <measurement group_id="O3" value="-1.8" spread="6.94"/>
                    <measurement group_id="O4" value="3.4" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.20"/>
                    <measurement group_id="O2" value="-1.5" spread="7.31"/>
                    <measurement group_id="O3" value="-1.0" spread="6.70"/>
                    <measurement group_id="O4" value="0.8" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.96"/>
                    <measurement group_id="O2" value="0.5" spread="9.21"/>
                    <measurement group_id="O3" value="-4.5" spread="7.54"/>
                    <measurement group_id="O4" value="1.6" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="6.41"/>
                    <measurement group_id="O2" value="-3.3" spread="7.09"/>
                    <measurement group_id="O3" value="-4.4" spread="9.29"/>
                    <measurement group_id="O4" value="-1.3" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="4.65"/>
                    <measurement group_id="O2" value="-3.0" spread="6.50"/>
                    <measurement group_id="O3" value="-1.9" spread="4.55"/>
                    <measurement group_id="O4" value="-0.9" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="7.98"/>
                    <measurement group_id="O2" value="-6.4" spread="5.78"/>
                    <measurement group_id="O3" value="-4.3" spread="4.83"/>
                    <measurement group_id="O4" value="0.0" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="7.00"/>
                    <measurement group_id="O2" value="-3.8" spread="7.76"/>
                    <measurement group_id="O3" value="-0.9" spread="6.53"/>
                    <measurement group_id="O4" value="1.5" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="4.75"/>
                    <measurement group_id="O2" value="-4.4" spread="7.56"/>
                    <measurement group_id="O3" value="-0.5" spread="4.69"/>
                    <measurement group_id="O4" value="-1.3" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was measured in the semi-recumbent position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without any distractions. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="4.84"/>
                    <measurement group_id="O2" value="-0.6" spread="6.67"/>
                    <measurement group_id="O3" value="1.4" spread="6.95"/>
                    <measurement group_id="O4" value="1.4" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="6.07"/>
                    <measurement group_id="O2" value="-0.5" spread="4.38"/>
                    <measurement group_id="O3" value="-1.3" spread="5.55"/>
                    <measurement group_id="O4" value="4.8" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.44"/>
                    <measurement group_id="O2" value="0.0" spread="7.93"/>
                    <measurement group_id="O3" value="2.5" spread="4.34"/>
                    <measurement group_id="O4" value="1.4" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="5.60"/>
                    <measurement group_id="O2" value="0.9" spread="4.94"/>
                    <measurement group_id="O3" value="2.8" spread="3.20"/>
                    <measurement group_id="O4" value="2.6" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiratory Rate</title>
        <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate</title>
          <description>Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.83"/>
                    <measurement group_id="O2" value="0.3" spread="2.71"/>
                    <measurement group_id="O3" value="-0.5" spread="2.33"/>
                    <measurement group_id="O4" value="0.3" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.12"/>
                    <measurement group_id="O2" value="2.0" spread="3.21"/>
                    <measurement group_id="O3" value="-0.3" spread="1.98"/>
                    <measurement group_id="O4" value="0.5" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.56"/>
                    <measurement group_id="O2" value="2.5" spread="2.07"/>
                    <measurement group_id="O3" value="0.0" spread="2.14"/>
                    <measurement group_id="O4" value="0.5" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.65"/>
                    <measurement group_id="O2" value="1.8" spread="4.06"/>
                    <measurement group_id="O3" value="1.3" spread="1.83"/>
                    <measurement group_id="O4" value="0.8" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Temperature</title>
        <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Days 2, 3, 4, and 5</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature</title>
          <description>Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.</description>
          <population>Safety Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.374"/>
                    <measurement group_id="O2" value="-0.10" spread="0.227"/>
                    <measurement group_id="O3" value="-0.15" spread="0.469"/>
                    <measurement group_id="O4" value="-0.10" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.433"/>
                    <measurement group_id="O2" value="-0.04" spread="0.311"/>
                    <measurement group_id="O3" value="-0.11" spread="0.253"/>
                    <measurement group_id="O4" value="-0.15" spread="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.262"/>
                    <measurement group_id="O2" value="-0.29" spread="0.429"/>
                    <measurement group_id="O3" value="-0.04" spread="0.450"/>
                    <measurement group_id="O4" value="-0.05" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.354"/>
                    <measurement group_id="O2" value="0.04" spread="0.256"/>
                    <measurement group_id="O3" value="-0.06" spread="0.250"/>
                    <measurement group_id="O4" value="0.10" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lag Time for Absorption (Tlag) for GSK3640254</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time for Absorption (Tlag) for GSK3640254</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.000" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.000" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Phase Half-life (t1/2) for GSK3640254</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Phase Half-life (t1/2) for GSK3640254</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.607" spread="18.7"/>
                    <measurement group_id="O2" value="22.001" spread="12.3"/>
                    <measurement group_id="O3" value="22.948" spread="29.2"/>
                    <measurement group_id="O4" value="24.448" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) for GSK3640254</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) for GSK3640254</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.632" spread="16.7"/>
                    <measurement group_id="O2" value="6.418" spread="37.4"/>
                    <measurement group_id="O3" value="12.87" spread="49.4"/>
                    <measurement group_id="O4" value="5.284" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for GSK3640254</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for GSK3640254</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Parameter Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.8" spread="30.8"/>
                    <measurement group_id="O2" value="203.7" spread="42.7"/>
                    <measurement group_id="O3" value="426.1" spread="70.7"/>
                    <measurement group_id="O4" value="186.4" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Concentration of GSK3640254</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK Concentration Population included all participants who underwent plasma PK sampling and had evaluable PK assay results.</description>
        <time_frame>Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose</time_frame>
        <population>PK Concentration Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
            <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Concentration of GSK3640254</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3640254. The PK Concentration Population included all participants who underwent plasma PK sampling and had evaluable PK assay results.</description>
          <population>PK Concentration Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean could not be calculated as it was below the limit of quantification; standard deviation (SD) could not be calculated due to the high proportion of NQ values (&gt;30% of values were imputed i.e. NQ assigned zero concentration) which affected the SD.</measurement>
                    <measurement group_id="O2" value="7.863" spread="NA">Standard deviation could not be calculated due to high proportion of non-quantifiable (NQ) values (more than [&gt;] 30 percent [%] of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O3" value="3.227" spread="NA">Standard deviation could not be calculated due to high proportion of NQ values (&gt;30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Mean could not be calculated as it was below the limit of quantification; standard deviation (SD) could not be calculated due to the high proportion of NQ values (&gt;30% of values were imputed i.e. NQ assigned zero concentration) which affected the SD.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="NA">Standard deviation could not be calculated due to high proportion of NQ values (&gt;30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation</measurement>
                    <measurement group_id="O2" value="68.15" spread="70.107"/>
                    <measurement group_id="O3" value="61.22" spread="75.133"/>
                    <measurement group_id="O4" value="443.0" spread="456.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.30" spread="87.234"/>
                    <measurement group_id="O2" value="291.1" spread="304.32"/>
                    <measurement group_id="O3" value="145.5" spread="121.20"/>
                    <measurement group_id="O4" value="696.0" spread="627.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.5" spread="176.30"/>
                    <measurement group_id="O2" value="486.0" spread="352.74"/>
                    <measurement group_id="O3" value="273.2" spread="206.53"/>
                    <measurement group_id="O4" value="837.6" spread="602.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.4" spread="267.01"/>
                    <measurement group_id="O2" value="746.1" spread="448.03"/>
                    <measurement group_id="O3" value="371.0" spread="261.44"/>
                    <measurement group_id="O4" value="946.3" spread="477.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490.3" spread="384.97"/>
                    <measurement group_id="O2" value="893.4" spread="398.47"/>
                    <measurement group_id="O3" value="412.4" spread="286.00"/>
                    <measurement group_id="O4" value="1009" spread="402.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647.1" spread="375.90"/>
                    <measurement group_id="O2" value="926.3" spread="194.74"/>
                    <measurement group_id="O3" value="477.2" spread="345.06"/>
                    <measurement group_id="O4" value="976.3" spread="339.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759.3" spread="334.79"/>
                    <measurement group_id="O2" value="955.8" spread="253.23"/>
                    <measurement group_id="O3" value="541.0" spread="463.54"/>
                    <measurement group_id="O4" value="1024" spread="350.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919.1" spread="287.70"/>
                    <measurement group_id="O2" value="1027" spread="320.44"/>
                    <measurement group_id="O3" value="624.0" spread="475.10"/>
                    <measurement group_id="O4" value="1027" spread="290.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1057" spread="172.77"/>
                    <measurement group_id="O2" value="1024" spread="278.55"/>
                    <measurement group_id="O3" value="560.3" spread="407.61"/>
                    <measurement group_id="O4" value="1067" spread="321.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1129" spread="204.39"/>
                    <measurement group_id="O2" value="1006" spread="231.01"/>
                    <measurement group_id="O3" value="523.5" spread="319.40"/>
                    <measurement group_id="O4" value="1001" spread="245.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020" spread="201.61"/>
                    <measurement group_id="O2" value="890.6" spread="277.11"/>
                    <measurement group_id="O3" value="471.8" spread="294.06"/>
                    <measurement group_id="O4" value="922.1" spread="238.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="793.1" spread="134.74"/>
                    <measurement group_id="O2" value="713.6" spread="247.97"/>
                    <measurement group_id="O3" value="359.5" spread="226.80"/>
                    <measurement group_id="O4" value="795.3" spread="206.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.8" spread="156.89"/>
                    <measurement group_id="O2" value="519.8" spread="184.90"/>
                    <measurement group_id="O3" value="262.7" spread="140.32"/>
                    <measurement group_id="O4" value="597.5" spread="175.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.0" spread="52.285"/>
                    <measurement group_id="O2" value="240.5" spread="84.134"/>
                    <measurement group_id="O3" value="124.2" spread="50.302"/>
                    <measurement group_id="O4" value="281.6" spread="75.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.0" spread="26.340"/>
                    <measurement group_id="O2" value="116.5" spread="38.362"/>
                    <measurement group_id="O3" value="56.97" spread="16.732"/>
                    <measurement group_id="O4" value="147.8" spread="56.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.26" spread="18.506"/>
                    <measurement group_id="O2" value="52.96" spread="17.846"/>
                    <measurement group_id="O3" value="28.18" spread="11.700"/>
                    <measurement group_id="O4" value="78.38" spread="39.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from start of the treatment (Day 1) up to Day 14</time_frame>
      <desc>Safety Population consisted of all participants who received at least 1 dose of study medication. Data is presented for Periods 1 and 2 only as data was not collected in Periods 3 and 4 due to early termination of the study following completion of Period 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A- GSK3640254 200 mg Capsules (Fed)</title>
          <description>Participants received a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions (Treatment A-reference) on Day 1 in treatment Period 1 or 2.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B- GSK3640254 200 mg Tablet (Fed)</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment B-test) on Day 1 in treatment Period 1 or 2.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C- GSK3640254 200 mg Tablet (Fasted)</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment C-reference) on Day 1 in treatment Period 1 or 2.</description>
        </group>
        <group group_id="E4">
          <title>Treatment D- GSK3640254 200 mg Tablet (High Fat)</title>
          <description>Participants received a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment D-test) on Day 1 in treatment Period 1 or 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

